Deutsche Bank
MBRX icon

Deutsche Bank’s Moleculin Biotech MBRX Stock Holding History

Deutsche Bank’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Hold
0
– -$1K – 4611
2019
Q4 		– Hold
0
– – – 4914
2018
Q2 		– Hold
0
– – – 5528
2018
Q1 		– Sell
-2
Closed -$8.65K – 5511
2017
Q4 		$7K Buy
2
+1
+100% +$4.33K ﹤0.01% 4819
2017
Q3 		$3K Buy
+1
New +$5.28K ﹤0.01% 4780

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deutsche Bank's MBRX Position: Q1 2020 in Review

Deutsche Bank held its Moleculin Biotech (MBRX) position steady in Q1 2020 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4611.

Deutsche Bank first reported a position in MBRX in Q3 2017 and has held it in 2 quarters since. The position peaked at $7K in Q4 2017. 17 funds tracked by Wall St. Rank hold MBRX as of Q1 2020.

  • Deutsche Bank held 0 shares of Moleculin Biotech worth $0 as of Q1 2020.
  • Deutsche Bank left its Moleculin Biotech share count unchanged in Q1 2020.
  • Moleculin Biotech made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2020, its #4611 holding.
  • Deutsche Bank first reported a position in Moleculin Biotech in Q3 2017 and has held it in 2 quarters since.
  • Deutsche Bank's Moleculin Biotech position peaked at $7K in Q4 2017.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2020.

Based on Deutsche Bank's 13F filing for Q1 2020, filed 14 May 2020.